We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Anti-Ganglioside Antibodies Analyzed in Celiac Disease

By LabMedica International staff writers
Posted on 29 Jun 2021
Print article
Image: Anti-Ganglioside Antibodies Analyzed in Celiac Disease (Photo courtesy of Blood Tests London)
Image: Anti-Ganglioside Antibodies Analyzed in Celiac Disease (Photo courtesy of Blood Tests London)
Celiac disease, sometimes called celiac sprue or gluten-sensitive enteropathy, is an immune reaction to eating gluten, a protein found in wheat, barley and rye. Coeliac disease can cause a range of symptoms, including diarrhea, abdominal pain and bloating.

Anti-ganglioside antibodies and analysis of the various human pathologies in which anti-ganglioside antibodies have been reported, including celiac disease (CD) as a condition associated with the presence of antibodies to ganglioside-monosialic acid (GM). Some scientists support the hypothesis that the formation of complexes between gliadin and GM1 ganglioside leads to the generation of antibodies to GM1 as a “secondary product”.

A team of Medical Scientists at the University of Bologna (Bologna, Italy) studied anti-GM1, anti-GD1b, and anti-GQ1b serum IgG and IgM antibodies in 22 adult patients (median age 35, range: 19–56 years; three males, 19 females) with CD and neurological manifestations, including eight cases of idiopathic cerebellar ataxia, seven cases with epilepsy (without cerebral calcifications), two with multiple sclerosis, three with attention/memory impairment, and two with peripheral neuropathies. In the study the team used a commercially available ELISA kit (IMMCO Diagnostics, Buffalo, NY, USA).

The investigators reported that at least one of the three anti-ganglioside IgG antibodies tested for (anti-GM1, anti-GD1b, and anti-GQ1b) was found in 64% of CD patients with neurological dysfunction compared to 30% of CD patients without neurological symptoms, 50% of neurological patients without CD, 20% of autoimmune controls and none of the healthy controls. No significant difference between groups was found for anti-GQ1b IgG.

Ganglioside reactivity, expressed in terms of Enzymatic Units (AEU) associated with anti-GM1 and anti-GD1b IgG were significantly higher in CD patients with neurological disorders than in CD patients without neurological disorders. Of note, eight (47%) of the 17 patients with CD and neurological manifestations who were positive for at least one anti-ganglioside IgG antibody became negative for the antibody after a year of strict adherence to a gluten-free diet. Interestingly, anti-ganglioside IgM antibodies, although at a lower prevalence than anti-ganglioside IgG antibodies and without any significant difference among the various groups studied, were confined to three cases of epilepsy within the CD group with neurological dysfunction.

The authors concluded that their study supports the potential pathogenic role of anti-ganglioside antibodies in immuno-mediated neurological disorders and provide evidence that detection of anti-ganglioside antibodies could indicate associated neurological symptoms in CD patients. Anti-ganglioside antibodies may therefore represent immunological markers for neurological dysfunction in CD patients and should be included in the work-up of CD patients. The study was published on May 28, 2021 in the journal Allergy, Asthma & Clinical Immunology.

Related Links:
University of Bologna
IMMCO Diagnostics


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.